Progression-Free and Overall Survival of Patients With ALK Rearrangement–Positive Non–Small Cell Lung Cancer Treated Sequentially With Crizotinib and Alectinib-Reference-Cited by-同舟云学术

Progression-Free and Overall Survival of Patients With ALK Rearrangement–Positive Non–Small Cell Lung Cancer Treated Sequentially With Crizotinib and Alectinib

Published:2016-11 Issue:6 Volume:17 Page:528-534
ISSN:1525-7304
Container-title:Clinical Lung Cancer
language:en
Short-container-title:Clinical Lung Cancer

Author:

Watanabe Satomi,Hayashi Hidetoshi,Okamoto Kunio,Fujiwara Kimiko,Hasegawa Yoshikazu,Kaneda Hiroyasu,Tanaka Kaoru,Takeda Masayuki,Nakagawa Kazuhiko

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference23 articles.

1. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer;Soda;Nature,2007

2. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer;Koivunen;Clin Cancer Res,2008

3. Anaplastic lymphoma kinase immunoreactivity correlates with ALK gene rearrangement and transcriptional up-regulation in non-small cell lung carcinomas;Boland;Hum Pathol,2009

4. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK;Shaw;J Clin Oncol,2009

5. EML4-ALK fusion lung cancer: a rare acquired event;Perner;Neoplasia,2008

Cited by 41 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tumor markers in non-small cell lung cancer spine metastasis: an assessment of prognosis and overall survival;European Spine Journal;2024-09-02

2. From Development to Place in Therapy of Lorlatinib for the Treatment of ALK and ROS1 Rearranged Non-Small Cell Lung Cancer (NSCLC);Diagnostics;2023-12-25

3. Clinical Characteristics of Patients with Advanced ALK-Translocated Non-small Cell Lung Cancers and Long-Term Responses to Crizotinib (CRIZOLONG GFPC 05-19 Study);Targeted Oncology;2023-11

4. Les patients ALK et ROS1 : quelle séquence ?;Revue des Maladies Respiratoires Actualités;2022-10

5. Crizotinib versus Alectinib for the Treatment of ALK-Positive Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis;Chemotherapy;2021-12-14